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INTRODUCTION
Cardiovascular disease (CVD) is the most important complica-
tion contributing to reduced life expectancy in patients with chronic
kidney disease (CKD) (1-3). Traditional and non-traditional risk
factors relating to the pathogenesis of CVD in CKD patients have
been identified (4, 5). Hyperphosphatemia has recently been rec-
ognized as a mediator between CKD and CVD (6, 7). Hyperphos-
phatemia is also an emerging problem, not only in CKD patients,
but also in the healthy population. Recent studies have demon-
strated that higher serum P levels, even those within the normal
range, were associated with the development of atherosclerosis and
mortality in the population with normal kidney function (8) and in
the Framingham Offspring Study participants (9). Onufrak et al.
also demonstrated that a high serum P level was associated with
thickening of the carotid artery intima media in the general popu-
lation (10). Hyperphosphatemia can induce the differentiation of vas-
cular smooth muscle cells to osteoblast - like cells that are involved
in the medial calcification of the artery, so-called Mönkeberg’s ar-
teriosclerosis (11-13). In addition, we and others have demonstrated
that hyperphosphatemia can also mediate endothelial dysfunction
(14-16), which is a principal cause of atherosclerosis resulting in
CVD.
Our previous study demonstrated that the ingestion of a high P
diet (1,200 mg P per meal) impaired flow-mediated dilation at 2 h af-
ter meal ingestion in young healthy men, compared with those given
a control diet (400 mg P per meal) (14). In addition, increasing the
extracellular P level induced increased oxidative stress and de-
creased nitric oxide production in bovine thoracic aorta endothe-
lial cells (14). Peng et al. reported that hyperphosphatemia de-
creased endothelial nitric oxide synthase (eNOS) expression in
human umbilical vein endothelial cells (15). DiMarco et al. also
demonstrated that an elevation of extracellular P can induce apop-
tosis via increased oxidative stress in human endothelial cell lines
(16). These results suggest that over a high dietary intake of P may
contribute to the pathogenesis of CVD. In this study, we performed
a double-blinded crossover study to investigate the dose- and
time-dependent effects of high dietary P intake on endothelial func-
tion in healthy human subjects.
METHODS
Subjects
Sixteen male volunteers aged 23.42.8 years and without appar-
ent health problems were recruited for this study. The participants
showed no evidence of diabetes, abnormal glucose intolerance, obe-
sity, hypertension, kidney diseases, CVD, dyslipidemia, or other
bone and mineral disorders. Demographic data for the participants
are provided in Table 1. All participants were nonsmokers, had
normal blood pressure, consumed30 g/d alcohol, and took no
medications or antioxidant supplements. The eligibility of partici-
pants for this study was determined similarly to our previous re-
ports (14, 17).
Study design
The study used a double-blinded crossover design, with the ad-
ministration of meals containing specific amounts of P to each vol-
unteer on 3 different days, each separated from the other test days
by more than 1 week. Figure 1 illustrates the design of the study.
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On the day before each test day, the subjects were asked to abstain
from foods and beverages other than water not containing P after
13 : 00. They were served a standard dinner at 20 : 00 on the eve-
ning before each test day, and a standard breakfast at 8 : 30 on each
test day. On the test days, subjects were served either a P400 meal
(standard lunch, which contained 400 mg of P+placebo supplement
(NaCl)), a P800 meal (standard lunch+400 mg neutralized phos-
phate supplement), or a P1200 meal (standard lunch+800 mg neu-
tralized phosphate supplement) for lunch at 12 : 30. The composi-
tion of the test meals and standard dinner and breakfast is provided
in our previous study. In brief, the standard dinner consisted of 700
kcal in energy with a protein : fat : carbohydrate ratio in %energy
of 15 : 19 : 66, and contained 200 mg of calcium (Ca) and 400 mg
of P. The standard breakfast consisted of 700 kcal with a protein :
fat : carbohydrate ratio in %energy of 14 : 21 : 65, and contained
200 mg of Ca and 400 mg of P. Standard lunch consisted of 700
kcal with a protein : fat : carbohydrate ratio in %energy of 14 : 21 :
65, and contained 200 mg of Ca and 400 mg of P.
We collected blood samples immediately before (0 h), and at 1 h,
2 h, 4 h, and 20 h after the test meal ingestion. Venous blood was
taken from a median cubital vein for the measurement of serum
glucose, insulin, P, Ca, Na, K, Cl, intact -PTH (iPTH) and high
sensitivity -C reactive protein (hs-CRP) concentrations. All bio-
chemical measurements and analyses were performed by LSI
Medience (Tokyo, Japan). Serum monocyte-chemoattractant
protein (MCP-1) and fibroblast growth factor 23 (FGF23) were
measured by CCL2/MCP-1 immunoassay kit (R&D Systems Inc.,
Minneapolis, MN) and FGF23 ELISA kit (Kinos, Tokyo, Japan),
respectively. We also measured blood pressure and flow-mediated
dilation (FMD) by using UNEXEF 18G (UNEX Corporation, Aichi,
Japan) according to previously published guidelines (18) imme-
diately before (0 h), and at 1 h, 2 h, 4 h, and 20 h after the test
meal ingestion.
The study protocols were approved by the Ethics Committee of
the Tokushima University Hospital. This study has been registered
and opened on the UMIN-CTR database in Japan according to the
ICMJE guidelines (UMIN000000803, Dietary phosphorus loading
trial in human).
Statistical analysis
We tested all data for normal distribution of variables of interests
by Kolmogorov-Smirnov test before further parametric or non-
parametric statistical analysis. If the test judged the data to be
normally distributed, we performed subsequent statistical analysis
by parametric analysis. If not, we used nonparametric analysis.
Serum biochemical measurements and %FMD within groups and
the effects of meals on pre-prandial and post-prandial values of these
measurements were analyzed by repeated measurements analysis
of variance (ANOVA) and post hoc analysis by Bonferroni’s method.
For the association analysis, we performed a simple regression
analysis and estimated Spearman’s non-parametric correlation co-
efficients. We selected the nonparametric procedure, which does
not require normally distributed data or linear associations of the
variables of interest.
We performed all statistical analyses using SPSS Statistics 17.0.
RESULTS
1. Dose and time-dependent effects of high dietary P intake on the
serum P level and other P metabolism-regulating factors
In this study, the subjects alternately received P400, P800, or
P1200 meals as lunch and the serum levels of P and P metabolism-
regulating factors were measured in the morning (fasting), and
before and after intake of the test meal (Table 2 and 3). In spite
of the differences in P content among the test meals, the serum
P level was significantly increased at 1 h, 2 h, and 4 h after the
ingestion of the test meals, compared with the pre-prandial serum
P level. However, the serum P levels at 1 h, 2 h, and 4 h after in-
gestion of the P1200 meal were significantly higher than that meas-
ured following ingestion of the P400 meal (Figure 2). Area under
the curve (AUC) analysis revealed post-prandial changes in the
serum P level during the 4 h after test meal ingestion ; the serum
P level was increased accordingly with the increases in phospho-
rus intake (Figure 3A). In addition, the serum P levels were above
the normal range at 1 h, 2 h, and 4 h after ingestion of the P800
or P1200 meals, but not after ingestion of the P400 meal. Serum
P levels had reverted to a normal level when measured the next
morning after ingestion of the test meals.
Serum intact -PTH levels did not show significant differences
among the groups ; however, they showed a biphasic peak at 1 h
and 4 h after ingestion of the test meals (Table 2), as reported
previously (17). The intact -PTH level at 4 h after ingestion of the
P400 and P1200 meals was significantly increased compared with
the pre-prandial serum intact -PTH level. The AUC for post-prandial
serum intact -PTH changes over 4 h increased accordingly with
the increases in the intake of P (Figure 3B). The AUC after the
ingestion of the P1200 meal was significantly greater than that after
the P400 meal (P0.05). FGF23 is also an important P metabolism-
regulating hormone. The serum FGF23 level was not increased
following ingestion of the test meals (Table 3). Serum Na, K, Cl,
Ca, hs-CRP, and MCP-1 levels also were not affected by the ex-
perimental increases in P intake (Tables 2 and 3).
2. Dose- and time-dependent effects of high dietary P intake on
FMD
We demonstrated that intake of the P1200 meal led to a signifi-
cant decrease in %FMD compared with that measured following
intake of the P400 meal at 2 h after meal ingestion (14). Here, we
investigated the dose- and time-dependent effects of high dietary
Table 1. Baseline characteristics of subjects.
Age 23.42.8
Height (cm) 171.52.8
Weight (kg) 60.45.1
Percentage body fat (%) 14.27.0
Body fat (kg) 8.83.5
Fat free mass (kg) 51.64.5
Muscle mass (kg) 48.94.3
Total body water (kg) 35.03.4
BMI (kg/m2) 20.52.1
Values are meanS.E.M., n=16.
Figure 1. Study schema. The three test meals containing different
amounts of P were served at 12 : 30 on the test day. The subjects were
allowed only the standardized water and meals that we supplied after
14 : 00 on the day before the test day. Asterisks indicate the times at which
blood collection and FMD measurements were performed.
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Table 2. Measurements of blood and urine biochemical markers.
%FMD SBP(mmHg)
DBP
(mmHg)
Glucose
(mg/dL)
Insulin
(μU/mL)
Na
(mEq/L)
K
(mEq/L)
Cl
(mEq/L)
Ca
(mEq/L)
P
(mEq/L)
Intact -PTH
(pg/dL)
Normal
Range
130 85 70 -109 1.7 -10.4 137 -147 3.5 -5.0 98 -108 8.4 -10.4 2.5 -4.5 10 -65
P4
00
m
ea
l
Morning 10.60.4 1172.1 70.32.1 91.92.2 3.930.5 1410.3 4.100.1 1030.5 9.890.1 4.020.1 41.02.9
Pre -prandial 11.10.3 1142.5 65.92.6 83.42.4 4.900.7 1400.4 4.310.1 1030.4 9.900.1 3.820.1 31.92.6
1 H 10.20.2 1162.6 63.12.1 96.93.9 16.51.7* 1420.5 4.040.1* 1040.5 9.650.1 4.130.1* 33.72.1
2 H 9.250.3 1152.4 64.11.8 1022.3 15.41.1* 1410.5 4.080.1* 1040.4 9.720.1 4.260.1* 32.42.2
4 H 10.20.4 1132.2 66.21.9 95.22.0 5.801.0 1410.4 4.220.1 1030.4 9.780.1 4.480.1* 40.72.5*
Next morning 10.60.3 1132.1 68.41.8 92.31.4 3660.3 1400.3 4.160.1 1030.4 9.860.1 3.910.1 33.51.6
P8
00
m
ea
l
Morning 10.10.4 1152.5 69.91.6 89.92.0 3.650.4 1400.3 4.080.1 1020.5 9.940.1 4.100.1 39.03.6
Pre -prandial 10.80.2 1132.8 65.02.0 82.62.5 6.942.0 1400.4 4.380.1 1030.3 9.840.1 3.810.1 33.12.5
1 H 6.650.4* 1152.5 63.81.5 95.94.1 16.71.6* 1410.5* 4.080.1* 1030.3 9.590.1 4.810.1* 39.62.1
2 H 5.890.5* 1132.4 62.51.8 1013.9 15.61.7* 1410.4* 4.080.1* 1020.4 9.630.1 4.890.1* 38.12.0
4 H 7.210.4* 1152.3 67.41.5 92.12.2 4.460.4 1400.3 4.140.1 1020.4 9.710.1 4.860.1* 39.63.3
Next morning 10.50.4 1132.6 67.32.0 91.51.5 3.580.3 1400.3 4.220.1 1020.4 9.930.1 3.890.1 34.73.4
P1
20
0
m
ea
l
Morning 9.990.3 1172.2 70.31.8 90.92.0 3.790.4 1400.5 4.140.1 1020.5 9.850.1 4.000.1 40.83.3
Pre -prandial 10.60.3 1162.6 66.92.1 81.12.9 5.100.9 1400.5 4.310.1 1030.3 9.890.1 3.750.1 33.62.7
1 H 5.280.4* 1152.4 63.11.8 1024.6 21.22.6* 1410.5* 3.990.1* 1030.4 9.590.1* 5.020.2* 41.72.5
2 H 5.620.4* 1162.4 64.91.7 97.13.3 14.11.0* 1410.5* 4.010.1* 1030.4 9.540.1* 5.260.2* 41.22.3
4 H 7.060.4* 1152.2 67.41.9 93.32.4 4.590.5 1410.4 3.980.1* 1020.3 9.660.1 5.230.1* 45.92.7*
Next morning 10.60.3 1162.4 67.31.4 91.61.7 3.830.4 1410.4 4.110.1 1030.3 9.810.1 3.930.1 32.52.1
P400, P400 meal ; P800, P800 meal ; P1200, P1200 meal ; %FMD, %flow-mediated dilation ; SBP, systolic blood pressure ; DBP, diastolic blood pres-
sure ; Cre, creatinine. Values are meanS.E.M. for 16 subjects. P0.05 vs pre -prandial in the same meal.
Figure 2. Effects of high dietary P intake (open diamond, P400 meal ;
open square, P800 meal ; open triangle, P1200 meal) on the serum P
level before and after ingestion of test meals. Data are meanS.E.M.
for 16 subjects.
Table 3. Effects of high dietary phosphorus intake on serum hs-CRP,
MCP-1, and FGF23 levels.
Pre -prandial 4 h Nextmorning
P4
00
m
ea
l hs -CRP
(mg/dL) 0.035
0.0 0.0340.0 0.0290.0
MCP-1 (pg/dL) 165.87.2 164.36.5 166.26.1
FGF23 (pg/mL) 41.616.5 35.716.7 45.015.5
P8
00
m
ea
l hs -CRP
(mg/dL) 0.048
0.0 0.0430.0 0.0350.0
MCP-1 (pg/dL) 165.76.7 157.26.8 160.95.9
FGF23 (pg/mL) 50.813.5 39.315.6 40.714.7
P1
20
0
m
ea
l hs -CRP
(mg/dL) 0.062
0.0 0.0610.0 0.0520.0
MCP-1 (pg/dL) 165.88.3 154.77.8 160.97.7
FGF23 (pg/mL) 60.616.7 40.116.2 49.218.4
Abbreviations are hs-CRP, high sensitive -C reactive protein ; MCP-1,
monocyte/macrophage chemoattractant protein -1 ; FGF23, fibroblast
growth factor 23.
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P intake on FMD in young healthy men. As shown in the Figure 4,
%FMD at 1 h, 2 h, and 4 h after the ingestion of P800 and P1200
meals was significantly decreased compared with that measured
following ingestion of the P400 meal. The peak inhibition of FMD
by P800 was observed at 2 h after meal ingestion, while that by P
1200 was at 1 h after meal ingestion. In addition, the decrease in
%FMD observed after high P intake was recovered by the next
morning. The rate of increase in the post-prandial serum P level
between 0-4 h after meal intake was significantly correlated with
the rate of decrease in %FMD (Figure 5).
DISCUSSION
In this study, we investigated the time- and dose-dependent ef-
fects of high dietary P intake on endothelial function by evaluat-
ing %FMD. We found that FMD was rapidly inhibited by high P
intake, but began to be recovered at 4 h and was normalized by
the next morning. We did not find any clear differences between
the P800 and P1200 meals in the high dietary P intake- induced
inhibition of FMD. However, the P1200 meal inhibited FMD slightly
faster than did the P800 diet. In addition, the inhibitory effect of
high dietary P intake could be observed at the minimum level of
intake of 800 mg of phosphorus in a single meal.
The post-prandial increase in the serum P level was significantly
Figure 3. Effects of high dietary P intake on areas under the curve for
post -prandial changes in serum P (A) and intact PTH levels (B) over 4 h
after ingestion of the test meal. Data are meanS.E.M. for 16 subjects.
**P0.01 for differences among the meals.
Figure 4. Effects of high dietary P intake (open diamond, P400 meal ;
open square, P800 meal ; open triangle, P1200 meal) on %FMD (B) be-
fore and after ingestion of test meals. Data are meanS.E.M. for 16
subjects.
Figure 5. Univariate association analysis of the ratios of changes (%)
in serum P and %FMD from pre-prandial measurements to those made
4 h after ingestion of the test meals. All variables were centralized ac-
cording to the median value for each individual. Each symbol is used
as in Figure 2. Spearman’s correlation coefficient (rs) and its P -value
for rs=0 are presented in the association.
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correlated with the degree of impairment of FMD. Our previous
work demonstrated that the experimental elevation of the extra-
cellular P level can inhibit nitric oxide production in endothelial
cells via increasing oxidative stress and the inhibitory phosphoryla-
tion of eNOS (14). Therefore, a transient increase in the serum P
level may be enough to lead to a deterioration of endothelial func-
tion. Another possible mechanism for the impairment of endothe-
lial function by a high serum P level is via PTH and FGF23. The
post-prandial serum PTH level was increased by high dietary P
intake in a dose-dependent manner. Primary hyperparathyroidism
patients have an impaired FMD (19-22), but the impairment of
FMD was ameliorated after parathyroidectomy (21, 20). Parathy-
roidectomy or Ca channel blockade was reported to restore inhib-
ited eNOS activity in a rat model of CKD (23). On the other hand,
FGF23 also can directly impair endothelium-dependent vasodila-
tion by increasing oxidative stress and reducing NO availability
(24). However, the serum FGF23 level was not increased after a
single ingestion of a high P meal in our study. Thus, the serum
FGF23 level did not appear to be related to the decreases in %FMD
observed in this study.
A transient increase in the serum P level may be an important
atherogenic factor. Watari et al. demonstrated that inducing fluc-
tuations in the serum P level by the alternating administration of
high or low P diets led to a deterioration of endothelium-depend-
ent vasodilation and an increased expression of VCAM-1 and MCP-
1 in the tunica intima (25). The impairment of endothelial function
by the alternating administration of high or low P diets was almost
same as that produced by the chronic administration of a high P
diet (25). Therefore, repeated transient increases in the serum P
level may have some of the same adverse effects on endothelial
cells as continuous high dietary P intake.
A chronic increase in the serum P level is a well -known risk
factor for CVD, not only in CKD patients, but also in the general
population (6, 10). In addition, Yamamoto et al. reported that a high
dietary P intake was associated with left ventricular hypertrophy
(26). They concluded that the highest quintile of dietary phospho-
rus intake (male 1,554-5,032 mg/day, female 1,346-4,069 mg/day)
was associated with an greater left ventricular hypertrophy com-
pared with the lowest quintile (male 270-687 mg/day, female 251-
585 mg/day). A recent study demonstrated that high dietary P in-
take was associated with all -cause mortality in the NHANES III
cohort (27). All -cause mortality was significantly increased in the
people with high phosphorus intake (more than 1,400 mg/day)
compared with low phosphorus intake (less than 1,400 mg/day). In
our study, standard P400 meal corresponded to 1,200 mg of daily
phosphorus consumption if the subject consumed the same meal
three times per day. On the other hand, the ingestion of P800 or
P1200 meal three times per day would be estimated over 1,400
mg/day. In this study, the single- time ingestion of P800 or P1200
meal significantly deteriorated endothelial function. Therefore, ha-
bitual consumption of high phosphorus diet likes P800 and P1200
meals may increase the risk of cardiovascular disease.
High phosphorus diet also causes large fluctuation of serum phos-
phorus levels. Portale et al. demonstrated that there is a circadian
rhythm of the serum P level (28), with the serum P level being at
its lowest during the morning fasting state and highest during the
night. A high dietary intake of P increased the serum P level dur-
ing both day and night, except during the morning fasting state.
Thus, a chronic high phosphorus diet can widen the amount of dif-
ference between the lowest and highest serum P levels present
during each circadian cycle. Such large daily fluctuations arising
from continuous high dietary P intake may cause endothelial dys-
function in humans, as was previously observed in rodents (25).
This study has some limitations. Firstly, this study was carried
out with a limited number, gender, and age range of subjects, al-
though the impact of these limitations was reduced by the use of
a double-blinded crossover protocol. A further intervention study
with a large number of subjects of different ages and genders
should be performed to confirm our results in the future. Secondly,
we could not fully clarify the effects of FGF23, PTH, or other fac-
tors on endothelial dysfunction caused by high dietary P intake. An
elevation or fluctuations in the serum P level must directly inhibit
endothelial function. However, PTH and FGF23 may be important
as mediators of the deterioration of endothelial function produced
by chronic high dietary P intake. Thus, a study investigating the
effects of the chronic administration of a high P diet is needed to
clarify the effects of PTH or FGF23 on the impairment of endo-
thelial function.
In conclusion, excessive dietary P intake can acutely impair en-
dothelial function in healthy people. Habitual excessive P intake
and the resulting endothelial dysfunction may contribute to the
progression of CVD or increased mortality, as is suggested by epi-
demiological data.
ACKNOWLEDGEMENTS
This work was supported by Grants- in-aid for Scientific Re-
search (B) (22300237) from the Japan Society for the promotion
of Science (JSPS) and the kidney foundation (JKFB08-22).
CONFLICT OF INTEREST
We have no conflicts of interest to declare for this study.
DISCLOSURE
No conflicts of interest are declared.
REFERENCES
1. Levin A : Clinical epidemiology of cardiovascular disease in
chronic kidney disease prior to dialysis. Semin Dial 16 : 101-
105, 2003
2. Kendric J, Chonchol M : Cardiovascular disease in CKD in
2013 : Reducing cardiovascular risk- light at the end of the
tunnel. Nat Rev Nephrol 10 : 71-72, 2014
3. Afsar B, Turkmen K, Covic A, Kanbay M : An update on coro-
nary artery disease and chronic kidney disease. Int J Nephrol
2014 : 767424. doi : 10.1155/2014/767424, 2014
4. Zoccali C, Mallamaci F, Tripepi G : Novel cardiovascular risk
factors in end-stage renal disease. J Am Soc Nephrol 15 : S77-
S80, 2004
5. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger
O, Massy Z : Emerging biomarkers for evaluating cardiovas-
cular risk in the chronic kidney disease patient : how do new
pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3 :
505-521, 2008
6. Kanbay M, Goldsmith D, Akcay A, Covic A : Phosphate- the
silent stealthy cardiorenal culprit in all stages of chronic kid-
ney disease : a systematic review. Blood Purif 27 : 220-230,
2009
7. Gupta D, Brietzke S, Hayden MR, Kurukulasuriya LR, Sowers
JR : Phosphate metabolism in cardiorenal metabolic disease.
Cardiorenal Med 1 : 261-270, 2011
8. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G : Relation be-
tween serum phosphate level and cardiovascular event rate in
people with coronary disease. Circulation 112 : 2627-2633,
2005
The Journal of Medical Investigation Vol. 62 August 2015 171
9. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D’Agostino RB Sr,
Gaziano JM, Vasan RS : Relations of serum phosphorus and
calcium levels to the incidence of cardiovascular disease in
the community. Arch Intern Med 167 : 879-885, 2007
10. Onufrak SJ, Bellasi A, Shaw LJ, Herzog CA, Cardarelli F,
Wilson PW, Vaccarino V, Raggi P : Phosphorus levels are as-
sociated with subclinical atherosclerosis in the general popu-
lation. Atherosclerosis 199 : 424-431, 2008
11. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori
K, Morii H, Giachelli CM : Phosphate regulation of vascular
smooth muscle cell calcification. Cir Res 87 : E10-E17, 2000
12. Giachelli CM : Vascular calcification : in vitro evidence for the
role of inorganic phosphate. J Am Soc Nephrol 14 : S300-S304,
2003
13. Moe SM, Chen NX : Pathophysiology of vascular calcification
in chronic kidney disease. Circ Res 95 : 560-567, 2004
14. Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato
M, Nashiki K, Amo K, Yamamoto H, Higashi Y, Nakaya Y,
Takeda E : Dietary phosphorus acutely impairs endothelial
function. J Am Soc Nephrol 20 : 1504-1512, 2009
15. Peng A, Wu T, Zeng C, Rakheja D, Zhu J, Ye T, Hutcheson J,
Vaziri ND, Liu Z, Mohan C, Zhou XJ : Adverse effects of simu-
lated hyper- and hypo-phosphatemia on endothelial cell func-
tion and viability. PLoS One 6 : e23268. doi : 10.1371/journal.
pone.0023268, 2011
16. Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P,
Wittkowski W, Lang D, Pavenstädt H : Increased inorganic
phosphate induces human endothelial cell apoptosis in vitro.
Am J Physiol Renal Physiol 294 : F1381-1387, 2008
17. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F,
Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto
H, Takeda E : Acute effect of oral phosphate loading on serum
fibroblast growth factor 23 levels in healthy men. Kidney Int
70 : 2141-2147, 2006
18. Corretti MC1, Anderson TJ, Benjamin EJ, Celermajer D,
Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-
Herman M, Herrington D, Vallance P, Vita J, Vogel R : Guide-
lines for the ultrasound assessment of endothelial -dependent
flow-mediated vasodilation of the brachial artery : a report of
the International Brachial Artery Reactivity Task Force. J Am
Coll Cardiol 39 : 257-265, 2002
19. Kosch M, Hausberg M, Vormbrock K, Kisters K, Rahn KH,
Barenbrock M : Studies on flow-mediated vasodilation and
intima-media thickness of the brachial artery in patients with
primary hyperparathyroidism. Am J Hypertens 13 : 759-764,
2000
20. Baykan M, Erem C, Erdogan T, Haclhasanoglu A, Gedikli Ö,
Klrls A, Kücükosmanoglu M, Ersöz H, Celik S : Impairment
of flow mediated vasodilatation of brachial artery in patients
with primary hyperparathyroidism. Int J Cardiovasc Imaging
23 : 323-328, 2007
21. Kosch M, Hausberg M, Vombrock K, Kisters K, Gabriels G,
Rahn KH, Barenbrock M : Impaired flow-mediated vasodila-
tion of the brachial artery in patients with primary hyperpara-
thyroidism improves after parathyroidectomy. Cardiovasc Res
47 : 813-818, 2000
22. Carrelli A, Walker MD, Di Tullio MR, Homma S, Zhang C,
McMahon DJ, Silverberg SJ : Endothelial function in mild pri-
mary hyperparathyroidism. Clin Endocrinol 78 : 204-209, 2013
23. Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ : Downregula-
tion of nitric oxide synthase in chronic renal insufficiency :
role of excess PTH. Am J Physiol Renal Physiol 274 : F642-
F649, 1998
24. Silswal N, Touchberry CD, Daniel DR, McCarthy DL, Zhang
S, Andresen J, Stubbs JR, Wacker MJ : FGF23 directly impairs
endothelium-dependent vasorelaxation by increasing super-
oxide levels and reducing nitric oxide bioavailability. Am J
Physiol Endocrinol Metab 307 : E426-E436, 2014
25. Watari E, Taketani Y, Kitamura T, Tanaka T, Ohminami H,
Abuduli M, Harada N, Yamanaka-Okumura H, Yamamoto H,
Takeda E : Fluctuating plasma phosphorus level by changes
in dietary phosphorus intake induces endothelial dysfunction.
J Clin Biochem Nutr 56 : 35-42, 2015
26. Yamamoto KT, Robinson-Cohen C, de Oliveira MC, Kostina
A, Nettleton JA, Ix JH, Nguyen H, Eng J, Lima JA, Siscovick
DS, Weiss NS, Kestenbaum B : Dietary phosphorus is associ-
ated with greater left ventricular mass. Kidney Int 83 : 707-
714, 2013
27. Chang AR, Lazo M, Appel LJ, Gutiérrez OM, Grams ME :
High dietary phosphorus intake is associated with all -cause
mortality : results from NHANES III. Am J Clin Nutr 99 : 320-
327, 2014
28. Portale AA, Halloran BP, Morris RC Jr : Dietary intake of phos-
phorus modulates the circadian rhythm in serum concentra-
tion of phosphorus. Implications for the renal production of
1,25-dihydroxyvitamin D. J Clin Invest 80 : 1147, 1154, 1987
T. Nishi, et al. Dietary phosphorus and endothelial function172
